Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?

被引:26
|
作者
Inal, Ali [1 ]
Kaplan, M. Ali [1 ]
Kucukoner, Mehmet [1 ]
Urakci, Zuhat [1 ]
Kilinc, Faruk [2 ]
Isikdogan, Abdurrahman [1 ]
机构
[1] Dicle Univ, Dept Med Oncol, Diyarbakir, Turkey
[2] Dicle Univ, Div Endocrinol, Diyarbakir, Turkey
关键词
Diabetes mellitus; Non-small cell lung; cancer; Prognostic factors; COLORECTAL-CANCER; LONGER SURVIVAL; GLUCOSE LEVEL; RISK; NSCLC; PREVALENCE; MORTALITY; IMPACT; BLOOD;
D O I
10.1016/j.rppneu.2013.09.001
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: It has been demonstrated that there are a lot of different prognostic factors which Non-small cell lung are worthy of consideration whereas diabetes mellitus (DM) has not been clearly or consistently identified as a prognostic value in advanced non-small cell lung cancer (NSCLC). The aim Prognostic factors of this study was to investigate the prognostic significance of the characteristics of patients in advanced NSCLC. Specifically, we investigated the impact of DM for progression-free survival (PFS) and overall survival (OS) in patients receiving first-line platinum-based doublets chemotherapy. Methods: We retrospectively reviewed 442 patients with advanced NSCLC. DM and other potential prognostic variables were chosen for analysis in this study. Univariate and multivariate analyses were conducted to identify prognostic factors associated with survival. Result: The results of univariate analysis for OS were identified as having prognostic significance: performance status (p < 0.001), stage (p < 0.001), DM (p < 0.001), liver metastasis (p = 0.02) and brain metastasis (p < 0.001). Stage, diabetes mellitus, and liver metastasis were identified as having prognostic significance for PFS. Multivariate analysis showed that poor performance status, presence of DM and advanced stage were considered independent negative prognostic factors for OS (p 0.001, p < 0.001 and p < 0.001 respectively). Furthermore, DM and stage were considered independent negative prognostic factors for PFS (p 0.005 and p 0.001 respectively). Conclusion: In conclusion, DM at the time of diagnosis was associated with the negative prognostic importance for PFS and OS in the advanced stage patients who were receiving first-line platinum-based doublets chemotherapy. In addition poor performance status and advanced stage were identified as negative prognostic factors. (c) 2013 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:62 / 68
页数:7
相关论文
共 50 条
  • [1] Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer?
    Pallis, A. G.
    Gridelli, C.
    [J]. CANCER TREATMENT REVIEWS, 2010, 36 (05) : 436 - 441
  • [2] Diabetes mellitus as a prognostic factor in advanced non-small-cell lung cancer. To be or not to be: That is as yet an unsolved question
    Sotto-Mayor, R.
    [J]. REVISTA PORTUGUESA DE PNEUMOLOGIA, 2014, 20 (02) : 57 - 59
  • [3] Influence of Diabetes mellitus of the Non-Small-Cell Lung Cancer
    Bartling, B.
    Sohst, A.
    Hofmann, H-S
    Silber, R-E
    Simm, A.
    [J]. ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2010, 43 : 136 - 136
  • [4] Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
    Imai, Hisao
    Kaira, Kyoichi
    Mori, Keita
    Ono, Akira
    Akamatsu, Hiroaki
    Matsumoto, Shunichi
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Harada, Hideyuki
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Yamada, Masanobu
    Takahashi, Toshiaki
    [J]. BMC CANCER, 2015, 15
  • [5] Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
    Hisao Imai
    Kyoichi Kaira
    Keita Mori
    Akira Ono
    Hiroaki Akamatsu
    Shunichi Matsumoto
    Tetsuhiko Taira
    Hirotsugu Kenmotsu
    Hideyuki Harada
    Tateaki Naito
    Haruyasu Murakami
    Masahiro Endo
    Takashi Nakajima
    Masanobu Yamada
    Toshiaki Takahashi
    [J]. BMC Cancer, 15
  • [6] Prognostic factors of advanced stage non-small-cell lung cancer
    Kwas, H.
    Guermazi, E.
    Khattab, A.
    Hrizi, C.
    Zendah, I.
    Ghedira, H.
    [J]. REVUE DE PNEUMOLOGIE CLINIQUE, 2017, 73 (04) : 180 - 187
  • [7] Treatment principles in advanced non-small-cell lung cancer
    Scott, CL
    Zalcberg, JR
    Irving, LB
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1996, 66 (10): : 688 - 693
  • [8] Gefitinib in the treatment of advanced non-small-cell lung cancer
    Reck, Martin
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) : 401 - 412
  • [9] Axitinib for the treatment of advanced non-small-cell lung cancer
    King, Judy W.
    Lee, Siow-Ming
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 765 - 773
  • [10] Afatinib for the treatment of advanced non-small-cell lung cancer
    Genova, Carlo
    Rijavec, Erika
    Barletta, Giulia
    Burrafato, Giovanni
    Biello, Federica
    Dal Bello, Maria Giovanna
    Coco, Simona
    Truini, Anna
    Alama, Angela
    Boccardo, Francesco
    Grossi, Francesco
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (06) : 889 - 903